Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUCT study
2022-500745-24-00Phase 3Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dutasteride, goserelin and bicalutamide in salivary duct carcinoma (SDC) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Overall response rate (ORR) and Duration of response (DoR). Planned start Aug 2022; status: authorised.
02
Drugs
dutasteridegoserelinbicalutamide
03
Conditions
salivary duct carcinoma (SDC)
Beyond the preview
Go deeper on 2022-500745-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500745-24-00.